pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Type 2 Diabetes · news · pharmadog
← back to Type 2 Diabetes
News mentioning Type 2 Diabetes
105
stories
2d
ObesityWeek 2026: Wave outlines case for body composition–based trial design
biospace
6d
Deep dive: Cardiovascular calamities and catalysts
biospace
9d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
10d
MedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
fda medwatch
11d
Lowering blood pressure after stroke or with diabetes poses challenges, in research and practice
stat
14d
A treatment revolution is underway in MASH
biospace
15d
Pfizer, fresh to China’s obesity market, looks to Viagra model to compete
biospace
21d
Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trial
fiercebiotech
21d
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
biospace
21d
Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
fiercebiotech
22d
‘The patient need is enormous’: Syntax programs stem cells into pancreatic beta cells in 4 days
fiercebiotech
Oct 19, 26
Should amylin have been obesity therapeutics’ primary target from the start?
biospace
Oct 14, 26
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
Oct 14, 26
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
biospace
Oct 9, 26
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
Oct 8, 26
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
biospace
Oct 8, 26
Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle
endpoints
Oct 8, 26
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
biospace
Oct 8, 26
Zealand, Roche’s ‘intriguing’ weight loss for amylin drug soured by blood sugar data
fiercebiotech
Oct 1, 26
STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
stat
Oct 1, 26
#EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesity
endpoints
Oct 1, 26
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
fiercebiotech
Sep 30, 26
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
Sep 30, 26
#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
endpoints
Sep 30, 26
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
stat
Sep 30, 26
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
Sep 30, 26
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
Sep 30, 26
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program
fiercebiotech
Sep 30, 26
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
fiercebiotech
Sep 29, 26
#EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold
endpoints
← prev
page 1 of 4
next →